After more than a decade in charge of the most influential organization representing the U.S. pharmaceutical industry, PhRMA, Steve Ubl will step down as its CEO at the end of the year. More: Steven Ubl set to depart after more
read moreJapan’s Shionogi is joining the spate of drugmakers to unveil a U.S. manufacturing commitment, albeit under slightly different circumstances than its peers. More: Shionogi nabs initial 9M award from BARDA to establish US antibiotic plant Source: fierce
read moreThe company is moving out of the building that used to house the headquarters of its 2022-acquired Global Blood Therapeutics. More: Pfizer walks away from 'underutilized' office space in South San Francisco, transitions employees to remote roles Source: fierce
read moreBiogen has agreed to a settlement with investors who claimed the company misled them in describing how it gained a controversial FDA approval for failed Alzheimer’s treatment, Aduhelm. More: Biogen settles investor lawsuit over its messaging on failed Alzheimer's drug
read moreWith a solid year of double-digit revenue growth in the books, Amgen’s longtime helmsman Robert Bradway continues to sit firmly in the upper echelons of biopharma CEO pay, though not quite at the level seen by some of his peers
read more
Subcutaneous delivery shows IV‑level efficacy in moderate to severe TED More: Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals